- Amgen Inc.
- Genentech Inc.
- Endo International PLC
- Eli Lilly & Co.
- Shionogi & Co. Ltd.
- Shionogi Inc.
- Biogen Inc.
- Celgene Corp.
- Genzyme Corp.
- Gilead Sciences Inc.
- Forest Laboratories Inc.
- Cephalon Inc.
- King Pharmaceuticals Inc.
- Alpharma LLC
- Mylan NV
- Merck KGaA
- Teva Pharmaceutical Industries Ltd.
- Barr Pharmaceuticals Inc.
- Pfizer Inc.
- Merck & Co. Inc.
- AtheroGenics Inc.
- Lilly comes out on top with $70/share ImClone bid
- Roche to gain full ownership of Genentech in $43.7bn deal
- Shionogi acquires Sciele Pharma for $1.4bn
- King offers $1.4bn cash for fellow spec pharma Alpharma
- Mylan wins war; buys Merck Generics for $6.7bn
- Teva boosts US/key European generics with $9bn Barr purchase
Ask The Analyst
Ask the Analyst is free for subscribers. Submit your question and one of our analysts will be in touch.
Your question has been successfully sent to the email address below and we will get back as soon as possible. firstname.lastname@example.org.
All fields are required.
All set! This article has been sent to email@example.com.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
Please Note: Only individuals with an active subscription will be able to access the full article. All other readers will be directed to the abstract and would need to subscribe.